Search

Displaying results 1901 - 1910 of 7186 in total
  1. Drug

    Asparagine

    go.drugbank.com/drugs/DB00174
    ApprovedNutraceuticalWithdrawn

    It is biosynthesized from aspartic acid and ammonia by asparagine synthetase. (From Concise Encyclopedia Biochemistry and Molecular Biology, 3rd ed)

    Mixtures: The Classeum Co., Ltd., The Classeum Co., Ltd.
  2. Drug

    Lodoxamide

    go.drugbank.com/drugs/DB06794
    Approved

    Lodoxamide is marketed under the brand name Alomide by Alcon.

    Synonyms: N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate
  3. Drug

    Hyoscyamine

    go.drugbank.com/drugs/DB00424
    ApprovedInvestigational

    [A228423] It is commonly extracted from plants in the _Solanaceae_ or nightshade family.[A228423] Research into the action of hyoscyamine in published literature dates back to 1826. … [A228713] Hyoscyamine is used for a wide variety of treatments and therapeutics due to its antimuscarinic properties.

    Mixtures: UR N-C Urinary Antiseptic, Urimar-T
  4. Indication

    Ventilator Associated Bacterial Pneumonia (VABP)

    go.drugbank.com/conditions/DBCOND0149717
    Drugs: Cefiderocol · Ceftolozane · Tazobactam · Telavancin
    Synonyms: Pneumonia due to bacteria NOS (disorder)
  5. Drug

    Troglitazone

    go.drugbank.com/drugs/DB00197
    ApprovedWithdrawn

    Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone].

  6. Drug

    Danaparoid

    go.drugbank.com/drugs/DB06754
    ApprovedWithdrawn

    While it was initially approved by the FDA as Orgaran™, danaparoid was withdrawn by Organon International on August 14, 2002, due to a shortage in drug substance by the manufacturer. … It is chemically distinct from heparin by containing different protein binding properties, thus has lower cross-reactivity in heparin-intolerant patients.

  7. Drug

    Ioxaglic acid

    go.drugbank.com/drugs/DB09313
    ApprovedWithdrawn

    Ioxaglic acid has a low osmolarity and is associated with fewer side effects compared to older contrast agents [L1883].

  8. Drug

    Influenza A virus A/Brisbane/10/2010 (H1N1) antigen (MDCK cell derived, propiolactone inactivated)

    go.drugbank.com/drugs/DB10998
    ApprovedInvestigationalWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

    Mixtures: Medical Provider Single Use EZ Flu Shot Flucelvax 2014-2015 Kit, Medical Provider Single Use EZ Flu Shot Flucelvax 2015-2016
  9. Drug

    Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB11044
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen … that it was previously exposed to.

    Mixtures: Medical Provider Single Use EZ Flu Shot Afluria 2016-2017, Medical Provider Single Use EZ Flu Shot Fluvirin 2016-2017
  10. Drug

    Dronabinol

    go.drugbank.com/drugs/DB00470
    ApprovedIllicitInvestigational

    associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments [FDA Label]. … If not provided in their activated form (such as through synthetic forms like Dronabinol or [DB00486]), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A